Reduction of bacteria and human immunodeficiency virus Type 1 infectivity of platelet suspension in plasma using xenon flash-pulse light in a bench-scale trial.
Current pathogen reduction systems for platelet concentrates (PCs) require addition of chemical compounds and/or reduction of plasma content in PCs. We have investigated a new method using xenon (Xe) flash-pulse light without additional compounds or plasma replacement.



An aliquot of apheresis platelets (PLTs) in plasma inoculated with bacteria or human immunodeficiency virus Type 1 (HIV-1) was irradiated with Xe flash-pulse light (Xe flash phototreatment). Bacterial growth was monitored up to 6 days of storage, whereas HIV-1 infectivity was assayed just after treatment. Pairs of Xe flash-phototreated and untreated PCs were examined for PLT lesion during the storage period.



Under the current conditions, a low titer (1.8 colony-forming units [CFUs]/mL) of Staphylococcus aureus did not proliferate during the 6-day storage period, but grew in some cases at high-titer (24.0 CFUs/mL) inoculation. HIV-1 infectivity was reduced by 1.8 log. PLT recovery of the treated PCs was lower than untreated ones. An increase of mean PLT volume and glucose consumption, together with a decrease of hypotonic shock response and pH, were enhanced by the treatment. CD62P- and PAC-1-positive PLTs increased after the treatment, indicating the induction of PLT activation. Among biologic response modifiers, soluble CD40 ligand was significantly increased in the treated PCs on Day 6.



Xe flash phototreatment could prevent bacterial proliferation and reduce HIV-1 infectivity in 100% plasma PCs without any additional compounds, but enhanced PLT storage lesions. Further improvement is required to increase the potency of pathogen inactivation with reducing PLT damage.
Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan. h-abe@jrc.or.jp.
Hideki
H
Abe
Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Masayuki
M
Shiba
Comet Co. Ltd, Tokyo, Japan.
Yoshiyuki
Y
Niibe
Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Kenji
K
Tadokoro
Central Blood Institute, Blood Service Headquarters, Japanese Red Cross Society, Tokyo, Japan.
Masahiro
M
Satake
D001792:Blood Platelets / Q000187:drug effects* / Q000382:microbiology / Q000528:radiation effects* / Q000821:virology; D001793:Blood Preservation / Q000379:methods; D004203:Disinfection / Q000379:methods; D015497:HIV-1 / Q000187:drug effects* / Q000528:radiation effects*; D006801:Humans; D013210:Staphylococcus / Q000187:drug effects* / Q000528:radiation effects*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000528:radiation effects; D014466:Ultraviolet Rays; D014978:Xenon
D014978:Xenon